1700062C10Rik Inhibitors encompass a diverse range of compounds specifically designed to modulate the activity of the 1700062C10Rik protein, a molecular entity of significant interest in biochemical research. This protein, encoded by a gene of the same nomenclature, plays a crucial role in various cellular processes, and its modulation is a focal point for the study of cellular mechanisms. The inhibitors targeting this protein exhibit a wide spectrum of chemical structures and properties, reflecting the ongoing evolution of chemical biology and medicinal chemistry. The molecular designs of these inhibitors are rooted in the principles of molecular recognition and interaction, where the inhibitors are structured to fit into the protein's active site or other relevant binding regions, thereby modulating its activity. This modulation is achieved through a variety of mechanisms, including competitive inhibition, where the inhibitor molecule competes with natural substrates or ligands for binding sites, allosteric inhibition, where binding occurs at a site distinct from the active site inducing conformational changes, and irreversible inhibition, where the inhibitor forms a covalent bond with the protein, leading to prolonged or permanent inhibition.
The development and study of 1700062C10Rik Inhibitors are driven by a deep interest in understanding the biochemical pathways in which the 1700062C10Rik protein is involved. These pathways, often complex and interconnected, play significant roles in cellular function and regulation. By modulating the activity of the 1700062C10Rik protein, these inhibitors serve as powerful tools in unraveling the intricacies of cellular mechanisms. They provide insights into the protein's role and its interactions with other molecular entities within the cell. The research in this field is not only focused on the direct interaction between the inhibitors and the 1700062C10Rik protein but also extends to the broader impact of this interaction on cellular pathways and networks. This comprehensive approach enables a more detailed understanding of cellular processes at the molecular level. Furthermore, the study of these inhibitors contributes to the advancement of chemical and biological methodologies, promoting the development of new techniques for molecular analysis and synthesis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin is involved in cell cycle pathways. Since 1700062C10Rik may be implicated in similar pathways, Cisplatin is shown to indirectly affect its activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib targets multiple receptor tyrosine kinases. It shown to influence pathways that involve proteins like CDK1, which could indirectly affect 1700062C10Rik activity. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide can inhibit topoisomerase II, impacting cell division. Its effect on cell cycle regulation pathways could indirectly influence 1700062C10Rik. | ||||||
2-Hydroxypropyl-β-cyclodextrin | 128446-35-5 | sc-203461 sc-203461B sc-203461C sc-203461A | 1 g 100 g 500 g 5 g | $52.00 $620.00 $1950.00 $130.00 | 8 | |
Influences cholesterol homeostasis and is shown to impact cell signaling pathways associated with 1700062C10Rik. | ||||||
Rottlerin | 82-08-6 | sc-3550 sc-3550B sc-3550A sc-3550C sc-3550D sc-3550E | 10 mg 25 mg 50 mg 1 g 5 g 20 g | $82.00 $163.00 $296.00 $2050.00 $5110.00 $16330.00 | 51 | |
Known to inhibit protein kinase C, which is shown to indirectly influence pathways associated with 1700062C10Rik. | ||||||